# **Special Issue**

# Advanced Research in Molecular Biology and Immunology of Gynecological Cancers

## Message from the Guest Editors

The purpose of this Special Issue is to present advanced research into the molecular mechanisms underlying interactions between cancer and immune cells in gynecological cancers. We invite authors to submit original research articles and reviews that focus on interactions between cancer and immune cells in terms of molecular mechanisms. We also invite authors to contribute articles that present exclusively molecular research on gynecological cancers, as well as research solely on cancer immunology. This Special Issue will be devoted to research on molecular interaction networks, new biomarkers, therapeutic targets, innovative cancer therapy, as well as research on the anticancer activity of compounds, including compounds of natural origin and their derivatives. Articles concerning the molecular mechanisms of drug resistance and toxicity of anticancer compounds are also welcome.

#### **Guest Editors**

Dr. Joanna Magdalena Gola

Dr. Barbara Strzałka-Mrozik

Dr. Aleksandra Mielczarek-Palacz

#### Deadline for manuscript submissions

closed (31 May 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/126826

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





# **About the Journal**

### Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).